Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03281798
Other study ID # 20220117-1
Secondary ID 16-008556
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date August 1, 2027

Study information

Verified date April 2024
Source University of Miami
Contact Rodrigo A Ruano, MD, PhD.
Phone 305.243.0769
Email rodrigo.ruano@miami.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to study the outcomes of maternal and fetal patients who are undergoing fetal intervention for severe isolated lower urinary tract obstruction (LUTO).


Other known NCT identifiers
  • NCT05368727

Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date August 1, 2027
Est. primary completion date August 1, 2027
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Pregnant women 2. Singleton pregnancy 3. Maternal age = 18 years 4. Male fetus with LUTO, dilated bladder, "keyhole sign" and bilateral hydronephrosis 5. Oligohydramnios or Anhydramnios 6. Favorable urine analysis defined as urinary sodium is < 100 milliequivalents per liter (mEq/L), chloride < 90 mEq/L, and osmolality < 200 milliosmoles per kilogram (mOsm/kg) after 20 weeks and in the absence of previous in utero intervention for the disease (vesicoamniotic shunt placement or fetal cystoscopy). 7. Absence of chromosomal abnormalities and associated anomalies 8. Gestational age at the time of the procedure will be between 16 0/7 weeks and 25 6/7 weeks 9. Normal karyotype by invasive testing (amniocentesis or Chorionic Villus Sampling (CVS)). Patients declining invasive testing will be excluded. 10. Family have considered and declined the option of termination of the pregnancy at less than 24 weeks. 11. Family meets psychosocial criteria, including sufficient social support and ability to understand requirements of the study. 12. Parents or guardian are willing to provide signed informed consent. Exclusion Criteria: 1. Fetal anomaly unrelated to LUTO 2. Congenital cardiac anomaly 3. Female fetus 4. Increased risk for preterm labor including short cervical length (<1.5 cm), history of incompetent cervix with or without cerclage, and previous preterm birth 5. Placental abnormalities (previa, abruption, accreta) known at time of enrollment 6. Contraindications to surgery including previous hysterotomy in active uterine segment 7. Technical limitations precluding fetoscopic surgery, such as uterine fibroids, fetal membrane separation, uterine anomalies incompatible with fetoscopy 8. Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy 9. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment 10. Maternal medical condition that is a contraindication to surgery or anesthesia 11. Patient does not have health insurance to cover routine clinical care including prenatal care, prenatal ultrasound, amniocentesis, tocolysis, admission, delivery, and fetal vesico-amniotic shunting. The exception will be fetal cystoscopy which is considered an experimental procedure. 12. Inability to comply with travel and follow-up requirements of the trial 13. Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy 14. Patients declining invasive testing 15. Family does not meet psychosocial criteria including insufficient

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Fetoscopes
Fetoscopes are telescopes developed for procedures involving fetal interventions and is inserted through the maternal abdomen.
Procedure:
Fetal Cystoscopy
A fetoscope will be inserted into the fetal bladder via the maternal abdomen and advanced into the fetal bladder outlet. Identified obstruction will be opened using laser.

Locations

Country Name City State
United States University of Miami Miami Florida
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Rodrigo Ruano

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants where the procedure was technically performed Number of participants where the fetal cystoscopy procedure was successfully technically performed. Day 1 (Post fetal cystoscopy procedure)
Primary Number of participants where the etiology of LUTO was correctly diagnosed Number of participants where the etiology of LUTO was correctly diagnosed during fetal cystoscopy as compared to post natal cystoscopy Up to 1 month post delivery
Primary Number of participants where the posterior urethral valve were successfully released Number of participants where the posterior urethral valve were successfully released Day 1 (Post fetal cystoscopy procedure)
Primary Number of participants whose fetal cystoscopy resulted in the prevention of post-natal severe pulmonary hypoplasia As per treating physician evaluation of clinical assessments post-natal. Up to 1 month post delivery
Primary Number of participants whose fetal cystoscopy resulted in the prevention of post-natal severe renal impairment As per treating physician evaluation of clinical assessments post-natal. Up to 24 months post delivery
Primary Number of participants whose fetal cystoscopy resulted in maternal complications Maternal and obstetrical complications such as preterm premature rupture of the membranes (PPROM), prematurity (birth <37 weeks), extremely preterm birth (<32 weeks), and urological fistulae and fetal demise. Day 1 post delivery
See also
  Status Clinical Trial Phase
Recruiting NCT03457805 - Prostatic Artery Embolization in Advanced Prostate Cancer N/A
Completed NCT00507455 - Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction Phase 2
Recruiting NCT04626167 - Concomitant Renal and Urinary Bladder Allograft Transplantation Early Phase 1
Not yet recruiting NCT06422312 - A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients. N/A
Suspended NCT01779349 - Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter" N/A
Not yet recruiting NCT01388348 - Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study N/A
Completed NCT00710749 - The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects N/A
Recruiting NCT03486639 - Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity
Enrolling by invitation NCT02869061 - Effectiveness and Safety of Adipose-derived Regenerative Cells for Reduction of Risk of Bladder Neck Contracture Phase 1/Phase 2
Active, not recruiting NCT05631080 - Transurethral Prostate Enucleation in Surveillance Protocol for Low Risk Prostate Cancer Phase 4
Completed NCT02031653 - Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test
Completed NCT00605319 - An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia Phase 4
Recruiting NCT03503721 - Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate N/A
Not yet recruiting NCT05910983 - Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity N/A
Completed NCT05470751 - GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
Completed NCT04981080 - DU and BOO in Women With and Without Symptoms of VD
Completed NCT00410514 - A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Phase 2
Recruiting NCT06152666 - Day-case Endourology; Enablers, Barriers, Unexpected Outcomes
Not yet recruiting NCT04514718 - Low Energy HoLEP on IPSS N/A
Completed NCT01661621 - Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Phase 4